Kaliumchlorid/Glucose B. Braun (Potassium Chloride, Glucose)

Potassium chloride dissociates in the bloodstream, releasing potassium ions that are taken up by cells. This helps restore normal membrane potential, supports cardiac and muscular function, and corrects low serum potassium levels. The accompanying glucose is metabolised to generate ATP, aiding cellular energy production and maintaining osmotic balance.

The dose is individualized by the prescribing clinician based on the patient’s serum potassium, glucose level, renal function, and overall clinical condition. Healthcare professionals calculate the required amount and infusion rate to safely achieve target electrolyte and glucose concentrations.

Safety data for use during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Enquiries are submitted through the product page on gnhindia.com. Provide the required quantity, and GNH India will verify institutional or trade credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain handling if needed) and any necessary import documentation.

Kaliumchlorid/Glucose B. Braun combines potassium chloride with glucose, offering simultaneous electrolyte correction and energy supplementation. Stand‑alone potassium chloride injections lack the glucose component, so separate dextrose solutions may be required to meet the same metabolic needs, potentially increasing preparation steps.

The injectable solution must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Before use, inspect for particulate matter or discoloration and allow the product to reach room temperature if required for infusion.

The solution is given intravenously, typically diluted in compatible IV fluids according to the prescriber’s instructions. Administration rate is adjusted based on the patient’s potassium and glucose targets, with continuous monitoring of serum levels and cardiac rhythm during infusion.

The most critical risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and anaphylactic or severe hypersensitivity reactions. Prompt recognition of chest pain, irregular heartbeat, or signs of an allergic response is essential, and immediate medical intervention should be initiated.

Patients with known hypersensitivity to potassium chloride or glucose, those with untreated hyperkalemia, severe renal failure without appropriate monitoring, and individuals with conditions that contraindicate rapid potassium infusion should avoid this product unless a clinician determines it is absolutely necessary.